In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
